Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 89Neoplasms 6HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Locally Advanced Breast Cancer 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

Trastuzumab 11pyrotinib 8pertuzumab 5Docetaxel 5trastuzumab deruxtecan 2Paclitaxel 2Carboplatin 2Capecitabine 2tucatinib 1pegfilgrastim 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Goserelin 1Fulvestrant 1Drug Therapy 1Anastrozole 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Breast Cancer × pertuzumab × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
80 enrolled
Breast

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

University of Kansas Medical Center

Phase 2 Unknown
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡